Farasat Zaman
Overview
Explore the profile of Farasat Zaman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
495
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang Z, Boggavarapu N, Arroyo Muhr L, Garcia-Serrango A, Aeppli T, Nava T, et al.
Cartilage
. 2024 Dec;
:19476035241302954.
PMID: 39655393
Objective: The genomic effects of biomechanical loading on human growth plate cartilage are unknown so far. To address this, we used rare human growth plate biopsies obtained from children undergoing...
2.
Soucek O, Cinek O, Velentza L, Semjonov V, Bezdicka M, Zaman F, et al.
Pediatr Res
. 2024 Apr;
96(4):952-963.
PMID: 38684886
Background: Glucocorticoids are commonly used in children with different chronic diseases. Growth failure represents a so far untreatable undesired side-effect. As lithium chloride (LiCl) is known to induce cell renewal...
3.
Velentza L, Wickstrom M, Kogner P, Ohlsson C, Zaman F, Savendahl L
J Endocr Soc
. 2024 Feb;
8(3):bvae009.
PMID: 38328478
Context: Recent preclinical studies reported that the BCL-2 inhibitor venetoclax can impair bone growth. A strategy to prevent such a side effect of this promising anticancer drug is highly desired....
4.
Zhao Y, Makitie O, Laakso S, Fedosova V, Savendahl L, Zaman F
Front Endocrinol (Lausanne)
. 2024 Feb;
14:1142310.
PMID: 38322155
Objective: Children with inflammatory bowel disease (IBD) often suffer from poor bone growth and impaired bone health. Humanin is a cytoprotective factor expressed in bone and other tissues and we...
5.
Landfeldt E, Phung K, Zaman F, Astrom E, Abner S, Lochmuller H, et al.
Neurology
. 2024 Jan;
102(2):e207948.
PMID: 38165327
Background And Objectives: Bisphosphonates are routinely used to treat osteoporosis in patients with Duchenne muscular dystrophy (DMD), a rare, severely debilitating neuromuscular disease. We sought to synthesize and grade benefits...
6.
Zhang Z, Zaman F, Nava T, Aeppli T, Gutierrez-Farewik E, Kulachenko A, et al.
Ann Biomed Eng
. 2023 Jun;
51(10):2229-2236.
PMID: 37314663
Mechanical loading has been described as having the potential to affect bone growth. In order to experimentally study the potential clinical applications of mechanical loading as a novel treatment to...
7.
Mistry J, Silvennoinen S, Zaman F, Savendahl L, Mariniello K, Hall C, et al.
Front Endocrinol (Lausanne)
. 2023 May;
14:1105602.
PMID: 37251684
Background: Fibroblast growth factor 21 (FGF21) is an essential metabolic regulator that adapts to changes in nutritional status. Severe childhood undernutrition induces elevated FGF21 levels, contributing to growth hormone (GH)...
8.
Velentza L, Wickstrom M, Kogner P, Ohlsson C, Zaman F, Savendahl L
Sci Rep
. 2023 May;
13(1):8054.
PMID: 37198212
Treatment-related skeletal complications are common in childhood cancer patients and survivors. Venetoclax is a BCL-2 inhibitor that has shown efficacy in hematological malignancies in adults and is being investigated in...
9.
Zhao Y, Celvin B, Denis M, Karagianni N, Aulin C, Zaman F, et al.
Sci Rep
. 2022 Oct;
12(1):18189.
PMID: 36307458
Children with chronic inflammation are often treated with glucocorticoids (GCs) and many of them experience growth retardation. It is poorly understood how GCs interact with inflammatory cytokines causing growth failure...
10.
Mushtaq I, Akhter Z, Farooq M, Jabeen F, Rehman A, Rehman S, et al.
Sci Rep
. 2021 Nov;
11(1):21507.
PMID: 34728694
The drug delivery system (DDS) often causes toxicity, triggering undesired cellular injuries. Thus, developing supramolecules used as DDS with tunable self-assembly and nontoxic behavior is highly desired. To address this,...